• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Pathog Glob Health . The suppressor of cytokine signaling-1 ( SOCS1) gene polymorphism and promoter methylation correlate with the course of COVID-

tetano

Editor, Senior Moderator
Pathog Glob Health


. 2022 Nov 29;1-9.
doi: 10.1080/20477724.2022.2151861. Online ahead of print.
The suppressor of cytokine signaling-1 ( SOCS1) gene polymorphism and promoter methylation correlate with the course of COVID-19


Tufan Tukek[SUP] 1 [/SUP], Sacide Pehlivan[SUP] 2 [/SUP], Alpay Medetalibeyoglu[SUP] 1 [/SUP], Istemi Serin[SUP] 3 [/SUP], Yasemin Oyacı[SUP] 2 [/SUP], Huzeyfe Arıcı[SUP] 1 [/SUP], Naci Senkal[SUP] 1 [/SUP], Mustafa Pehlivan[SUP] 4 [/SUP], Ummuhan Isoglu-Alkac[SUP] 5 [/SUP], Murat Kose[SUP] 1 [/SUP]



Affiliations

Abstract

The suppressor of the cytokine signaling-1 (SOCS1) gene is a short sequence located on chromosome 16 that functions to induce an appropriate immune response and is an essential physiological regulator of interferon (IFN) signaling. In addition to comparing the global DNA and SOCS1 gene promoter methylation status between our patients with coronavirus disease 2019 (COVID-19) and healthy controls, this study demonstrates the effect of the SOCS1 rs33989964 polymorphism on patients with COVID-19. The study group included 139 patients diagnosed with COVID-19 in our hospital's clinics between June and December 2020, and the control group included 78 healthy individuals. After comparing the initial gene polymorphisms of the patients with the healthy control group, three separate clinical subgroups were formed. The gene polymorphism distribution and the methylation status of SOCS1 were examined in these clinical subgroups. Hypomethylation of the SOCS1 gene was observed in the COVID-19 patient group compared to the healthy control group (p = 0.001). Between the patients divided into two separate clinical subgroups, those with severe and mild infections, the Del/Del genotype of the SOCS1 gene was more common in patients with severe infection than in patients with mild infection (p = 0.018). Patients with the CA/CA and CA/Del genotypes were 0.201 times more likely to have a severe infection (95% CI: 0.057-0.716, p = 0.007). Having a non-Del/Del genotype was a protective factor against severe infection. The effect of the SOCS1 rs33989964 polymorphism and methylation status of the SOCS1 gene throughout the COVID-19 pandemic could be significant contributions to the literature.

Keywords: COVID-19; SOCS1; methylation; mortality; polymorphism; prognosis.
 
Back
Top Bottom